erlotinib has been researched along with streptomycin in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (streptomycin) | Trials (streptomycin) | Recent Studies (post-2010) (streptomycin) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 22,227 | 362 | 1,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, W; Ibrar, A; Khan, I; Saeed, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for erlotinib and streptomycin
| Article | Year |
|---|---|
Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: the advances continue.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Glucuronidase; Humans; Molecular Structure; Phosphotransferases; Quinazolines; Quinazolinones; Tetrahydrofolate Dehydrogenase | 2015 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |